NVS Stock Recent News
NVS LATEST HEADLINES
Novartis AG (NYSE:NVS ) Q2 2025 Earnings Conference Call July 17, 2025 8:00 AM ET Company Participants Harry Kirsch - Chief Financial Officer Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division Florent Cespedes - Societe Generale Cross Asset Research Harry Thomas d'Alton Sephton - Crédit Suisse AG, Research Division James Patrick Quigley - Goldman Sachs Group, Inc., Research Division Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Michael Leuchten - UBS Investment Bank, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Peter Verdult - BNP Paribas Exane, Research Division Rajesh Kumar - HSBC Global Investment Research Richard Vosser - JPMorgan Chase & Co, Research Division Sachin Jain - BofA Securities, Research Division Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division Shirley
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Here is what you may have missed on Market Catalysts for Thursday, July 17. Uber and Lucid are partnering on a new robotaxi service.
Novartis CEO Vas Narasimhan said Thursday that the company is in open discussions with the Trump administration over pharmaceutical tariffs, aiming to strike a balance between lowering patient costs and preserving U.S. leadership in biomedical innovation.
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs, plus robust financials and buybacks, position Novartis for resilience despite upcoming revenue headwinds. While the company's long-term outlook remains positive, current valuation already reflects its strengths, making shares fairly valued at this time.
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.